AUTHORS
Naseema Gangat, MBBS, Ayalew Tefferi, MD2, Prithviraj Bose, MD3, Aaron T. Gerds, MD, MS4, Lisa Guiducci, MD5, Michael R. Grunwald, MD6, Anna Halpern, MD7, Stephen Oh, MD, PhD8, Caitlin O'Neill, MD9, Lindsay Rein, MD10, Candido E Rivera, MD11, Gary J. Schiller, MD12, Joseph Shatzel, MD13, Jennifer E Vaughn, MD, MSPH14, Anne Wofford, MD15, Marcus Carden, MD, MSc16, Shuai Chen, PhD, MS17, Alison Kracunas18, Guowen Liu19, Daphne Yang20, Will Savage, MD, PhD21, Jeanne Palmer, MD22, Naveen Pemmaraju, MD23
AFFILIATIONS
1 Mayo Clinic, Rochester, Minnesota, United States
2 Mayo Clinic, Rochester, Minnesota, United States
3 MD Anderson Cancer Center, Houston, Texas, United States
4 Cleveland Clinic, Cleveland, Ohio, United States
5 Oregon Health & Science University, Portland, Oregon, United States
6 Atrium Health Levine Cancer Institute, Charlotte, North Carolina, United States
7 University of Washington School of Medicine - Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
8 Washington University in St. Louis School of Medicine - Siteman Cancer Center, St. Louis, Missouri, United States
9 USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
10 Duke University School of Medicine, Durham, North Carolina, United States
11 Mayo Clinic, Jacksonville, Florida, United States
12 David Geffen School of Medicine at UCLA, Los Angeles, California, United States
13 Oregon Health & Science University, Portland, Oregon, United States
14 Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
15 Atrium Health Wake Forest Baptist, Winston-Salem, North Carolina, United States
16 Disc Medicine, Watertown, Massachusetts, United States
17 Disc Medicine, Watertown, Massachusetts, United States
18 Disc Medicine, Watertown, Massachusetts, United States
19 Disc Medicine, Watertown, Massachusetts, United States
20 Disc Medicine, Watertown, Massachusetts, United States
21 Disc Medicine, Watertown, Massachusetts, United States
22 Mayo Clinic, Phoenix, Arizona, United States
23 MD Anderson Cancer Center, Houston, Texas, United States
ABSTRACT
Background: Polycythemia vera (PV) is a myeloproliferative neoplasm associated with pathologic erythrocytosis driven primarily by somatic mutations in the Janus kinase (JAK) 2 gene. Current standard of care to maintain hematocrit (HCT) <45%, including phlebotomy (PHL), can be burdensome, may lead to intolerable adverse effects, and can be associated with symptoms of iron deficiency. DISC-3405 is an investigational, novel, humanized immunoglobulin (Ig)G1 monoclonal antibody (mAb) that targets transmembrane serine protease 6 (TMPRSS6, also known as matriptase-2) to stimulate endogenous production of hepcidin to restrict iron availability for erythropoiesis, and thereby reduce HCT. RESTORE-PV (NCT06985147) is a multicenter, open-label, 52-week Phase 2 study assessing safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and therapeutic effect of DISC-3405 on PV disease control as evidenced by HCT control, PHL requirements, and measures of quality of life.
Methods: Eligible participants met 2022 World Health Organization (WHO) diagnostic criteria, required ≥3 PHLs in 26 weeks or ≥5 PHLs in 52 weeks prior to screening, with at least 1 PHL within 12 weeks. Stable cytoreductive therapy (CRT; ie, hydroxyurea [HU], interferon [IFN], ruxolitinib) was allowed.
Participants received DISC-3405 subcutaneously in Cohort A (maintenance treatment: 300 mg Q2 weeks; n=20) or Cohort B (maintenance treatment: 300 mg Q4 weeks; n=20). Main efficacy endpoints include proportion of participants who remained PHL-free, did not meet PHL eligibility, and number of PHLs compared to baseline. PHL eligibility is defined as confirmed HCT ≥45% and ≥3% increase (absolute change) from Day 1 or confirmed HCT >48%. Baseline PHL rates are defined as PHL rate 26 weeks prior to Day 1 of dosing. Change from baseline in iron metabolism PD markers and patient symptom burden scores are additional endpoints. The primary safety objective is to establish safety and tolerability of DISC-3405 in a PV population requiring PHL for disease control.
Results: As of the data cut on 13 Jul 2026, all 40 participants were enrolled and 38 dosed (n=20 in Cohort A and n=18 in Cohort B). Follow-up is ongoing for all participants. Demographics and other baseline characteristics of the 38 dosed participants: mean age of 59.4 years, 63.2% male, 94.7% identified as White, mean time since diagnosis of 5.6 years, 97.4% with JAK2 V617F mutation, 52.6% on CRT (42.1% HU, 15.8% IFN; n=2 on both), and mean baseline PHL rate 3.8 (weekly rate 0.15). Mean time in study for those dosed was 205.5 days for Cohort A and 65.0 days for Cohort B. The PK profiles observed were consistent with a typical mAb and aligned with the projections based on an established population PK model; no anti-drug antibody was observed. Weekly PHL rate (mean [SD]) of Cohort A participants who received DISC-3405 for at least 26 weeks (n=13) significantly decreased from baseline PHL rate: 4.0 (weekly rate 0.15 ) to 0.6 (weekly rate 0.02) in 26 weeks (p<0.0001; 95% CI mean difference, -4.5, -2.3 [weekly rate: -0.17, -0.09]), with 8 participants (61.5%) remaining PHL-free during this period, which included dose escalation. In Cohort A, between Day 1 (n=20) and Week 26 (n=13 for HCT, n=9 for other biomarkers), mean (SD) HCT remained stable at 43.0% (1.5) to 43.3% (1.3), hepcidin increased from 0.3 ng/mL (0.3) to 11.6 ng/mL (11.8), and serum iron and transferrin saturation decreased from 26.2 ug/dL (16.1) to 20.4 (7.0) and 6.3% (4.2) to 5.2% (1.6), respectively. Ferritin increased from 14.2 ng/mL (7.9), consistent with iron deficiency, to 33.1 ng/mL (25.2) during the same period, suggesting a redistribution of iron stores. DISC-3405 was generally safe and well tolerated in all dosed participants from both Cohort A and B. Most treatment-emergent adverse events (TEAEs) were Grade 1. Injection site reactions occurred in 13.2% (n=5) of participants, all Grade 1 and self-limited. No TEAEs led to discontinuation; 3 participants voluntarily withdrew from the study. One participant in Cohort B had anemia requiring dose reduction. Updated safety, PK, PD, and efficacy results from Cohorts A and B will be presented.
Conclusion: DISC-3405 was generally safe and well tolerated, led to increased hepcidin and reduced serum iron, controlled HCT, and reduced PHL burden in participants with PV.
DISCLOSURES
Naseema Gangat, MBBS: No relevant conflicts of interest to declare.